Adjunct to diet for patients w/ elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B (apo B) & triglycerides & to increase HDL-cholesterol (HDL-C) in patients w/ primary hypercholesterolemia (heterozygous familial & non-familial), combined (mixed) hyperlipidemia, elevated serum triglyceride levels & for patients w/ dysbetalipoproteinemia who do not respond adequately to diet. Reduction of total-C & LDL-C in patients w/ homozygous familial hypercholesterolemia. Prevention of CV disease w/o clinically evident CHD but w/ multiple risk factors eg, age, smoking, HTN, low HDL-C or family history of early CHD for reduction of risk of MI, stroke, revascularisation procedures & angina. In type 2 diabetes w/o clinically evident CHD but w/ multiple risk factors eg, retinopathy, albuminuria, smoking or HTN for reduction of risk of MI & stroke. In patients w/ clinically evident CHD for reduction of risk of non-fatal MI, fatal & non-fatal stroke, angina, revascularisation procedures & hospitalisation for CHF. Adjunct to diet to reduce total-C, LDL-C & apo B levels in boys & postmenarchal girls 10-17 yr w/ heterozygous familial hypercholesterolemia if LDL-C ≤190 mg/dL or ≥160 mg/dL & there is a positive family history of premature CV disease or ≥2 other CV disease risk factors remains after adequate diet therapy.